| Nanomedicine: Self-assembled biomaterials as next-generation therapeutics | Concepts |
|---|---|
|
Molecular Design in Nanomedicine My lab’s central theme is to harness the potential of self-assembled or polymeric nanomaterials as ‘next-generation biomaterials’ in the field of translational research to solve unmet biomedical needs. The application of nanotechnology to drug delivery widely expected to change the landscape of pharmaceutical and biotechnology industries and orientation of translational research for the foreseeable future. The pipelines of pharmaceutical companies believed to be drying up in many cases, and a number of blockbuster drugs will come off patent in the near-term. The development of nanotechnology products would play an important role in adding a new armamentarium of therapeutics to the pipelines of pharmaceutical companies while contributing paradigm-changing science to the translational research. My lab utilizes nanotechnology as a basic tool, and by combining with clinical research, we aim to achieve an improved delivery of drugs, genes or cells as next-generation therapeutic strategies. Inflammation, a primary defence system, also an inherent part of most diseases. It plays varient roles in different diseases, thus developing inflammation-resposive biomaterials could be a paradigm shift in the treatment/management of diseases. This is particularly huge leap for the treatment of inflammatory/autoimmune diseases. My lab is focused on developing therapeutics for the treatment of inflammatory diseases: Inflammation-responsive drug delivery platform will be utilized for: - To prevent rejection episodes in organ transplantation Collaborators - Robert Rieben : University Hospital of Bern, Switzerland |
 Self-assembled prodrugs - A new paradigm in drug delivery  |